Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20064103 | 0.82 | ALDH1A1 (0.52) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL3205032 | 0.79 | CYP3A4 (0.53) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL12457525 | 0.79 | GPR119 (0.37) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL25217781 | 0.78 | PTPN11 (0.31) | ALDH1A1HSD17B10HPGD | |
| SCHEMBL12459109 | 0.75 | ACACB (0.33) | KMT2AMEN1 | |
| SCHEMBL24921476 | 0.75 | PTPN11 (0.39) | ALDH1A1HSD17B10HPGDLMNAMAPT | |
| SCHEMBL24921747 | 0.71 | GPR119 (0.36) | CYP3A4KDM4ERAB9A | |
| SCHEMBL20064104 | 0.70 | HSD17B10 (0.43) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL17135754 | 0.70 | HSD17B10 (0.69) | ALDH1A1HSD17B10HPGDCYP3A4USP2 | |
| SCHEMBL16236124 | 0.68 | ALDH1A1 (0.53) | ALDH1A1HSD17B10HPGDCYP3A4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192822-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | claimed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| WO-2018069863-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | ALDH1A1 222/4885HSD17B10 466/4885HPGD 7/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | ALDH1A1 222/4885HSD17B10 466/4885HPGD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.